Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCRX.L Regulatory News (CRX)

  • There is currently no data for CRX

Statement re Unsolicited Approach

2 Mar 2010 07:00

RNS Number : 9142H
Cyprotex PLC
02 March 2010
 



2 March 2010

 

 

Cyprotex PLC

("Cyprotex" or the "Company")

 

 

Statement re Unsolicited Approach

In light of the recent share price movements the Board of Cyprotex (AIM: CRX) announces that it has received a highly preliminary and unsolicited approach regarding a potential offer for the Company.

It should be noted that there is no certainty that an offer will be forthcoming.

This announcement has been made without the consent of the party who made the approach.

In accordance with Rule 2.10 of The City Code on Takeovers and Mergers (the 'Code'), Cyprotex confirms that, as at the date of this announcement it had 178,957,188 ordinary shares of 0.01 pence each in issue.

 

Enquiries:

 

Cyprotex PLC

 

Anthony Baxter CEO

016 2552 5100

 

ir@cyprotex.com

www.cyprotex.com

 

 

Execution Noble & Company Limited

 

John Llewellyn-Lloyd

020 7456 9191

 

Sam Reynolds

 

 

Public Relations

 

Financial Dynamics

 

Ben Brewerton

020 7831 3113

 

Ben Atwell

 

John Dineen

 

 

 

 

Dealing Disclosure Requirements

 

Under the provisions of Rule 8.3 of the City Code on Takeovers and Mergers (the 'Code'), if any person is, or becomes, 'interested' (directly or indirectly) in 1% or more of any class of 'relevant securities' of the Company, all 'dealings' in any 'relevant securities' of the Company (including by means of an option in respect of, or a derivative referenced to, any such 'relevant securities') must be publicly disclosed by no later than 3.30pm (London time) on the London business day following the date of the relevant transaction. This requirement will continue until the date on which the offer becomes, or is declared, unconditional as to acceptances, lapses or is otherwise withdrawn or on which the 'offer period' otherwise ends. If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire an 'interest' in 'relevant securities' of the Company, they will be deemed to be a single person for the purpose of Rule 8.3.

 

Under the provisions of Rule 8.1 of the Code, all 'dealings' in 'relevant securities' of the Company by the Company or by any of its respective 'associates', must be disclosed by no later than 12.00 noon (London time) on the London business day following the date of the relevant transaction.

 

A disclosure table, giving details of the companies in whose 'relevant securities' 'dealings' should be disclosed, and the number of such securities in issue, can be found on the Takeover Panel's website at www.thetakeoverpanel.org.uk.

 

'Interests in securities' arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in price or securities. In particular, a person will be treated as having an 'interest' by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities.

 

Terms in quotation marks are defined in the Code, which can be found on the Panel's website. If you are in any doubt as to whether or not you are required to disclose a 'dealing' under Rule 8, you should consult the Panel.

 

If you are in any doubt as to the application of Rule 8 to you, please contact an independent financial advisor authorised under the Financial Services and Markets Act 2000, consult the Panel's website at www.thetakeoverpanel.org.uk or contact the Panel on telephone number +44 20 7638 0129; fax +44 20 7236 7013.

 

The Directors of the Company accept responsibility for the information contained in this announcement. To the best of knowledge and belief of the Directors, who have taken all reasonable care to ensure such is the case, the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

 

Execution Noble & Company Limited is acting for the Company and for no-one else in connection with the possible offer for the Company and will not regard any other person as its client nor be responsible to anyone other than the Company for providing the protections afforded to clients of Execution Noble & Company Limited nor for providing advice in relation to the possible offer or any matter referred to herein. Execution Noble & Company Limited, is authorised and regulated by the Financial Services Authority in respect of regulated activities.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
OFDQLLBBBXFZBBQ
Date   Source Headline
7th Apr 20164:11 pmRNSForm 8.3 - Cyprotex PLC
7th Apr 20161:42 pmRNSForm 8.3 - Cyprotex
7th Apr 20169:37 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
6th Apr 20169:19 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
5th Apr 20163:10 pmRNSForm 8.3 - Cyprotex PLC
5th Apr 20169:30 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
4th Apr 201612:36 pmBUSForm 8.3 - Cyprotex Plc
4th Apr 201612:01 pmRNSForm 8.3 - Cyprotex plc
4th Apr 201610:32 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
4th Apr 201610:31 amPRNForm 8.3 - Cyprotex Plc
1st Apr 20163:58 pmRNSForm 8.3 - Cyprotex Plc
1st Apr 20167:02 amRNSStrategic Review
1st Apr 20167:01 amRNSNotice of General Meeting
1st Apr 20167:00 amRNSFinal Results
31st Mar 201610:58 amRNSLaunch of Advanced 3D Liver Model
29th Mar 20167:00 amRNSChanges to UK reporting framework
9th Mar 20167:00 amRNSLaunch of New Chemical and Cosmetics Testing Guide
10th Feb 20167:00 amRNSStrategic partnering deal with Cytocentrics
21st Jan 20167:00 amRNSExecutive Option Scheme
17th Dec 20159:09 amRNSTrading Update
17th Nov 20157:00 amRNSLaunch of Solution to Predict Preclinical Toxicity
23rd Oct 20157:00 amRNSTrading Update
15th Oct 20157:00 amRNSLaunch of New ADME Guide
13th Oct 20157:00 amRNSPartnership in the EC funded EU-ToxRisk consortium
8th Oct 20157:00 amRNSConversion of Loan Notes, Directors Dealing & TVR
21st Sep 20158:40 amRNSHolding(s) in Company
19th Aug 201512:02 pmRNSHolding(s) in Company
18th Aug 20157:00 amRNSInterim Results 2015
16th Jul 20157:00 amRNSLaunch of new Biosciences division
14th Jul 20157:00 amRNSLaunch of new chemPK workflow solution
10th Jul 201510:32 amRNSHolding(s) in Company - REPLACEMENT
10th Jul 201510:29 amRNSHolding(s) in Company - REPLACEMENT
9th Jul 20151:01 pmRNSHolding(s) in Company
9th Jul 20151:00 pmRNSHolding(s) in Company
17th Jun 201510:26 amRNSResult of AGM
1st Jun 20157:00 amRNSTrading Update
22nd May 20157:00 amRNSPublication of Annual Report & Notice of AGM
6th May 20157:02 amRNSHolding(s) in Company
15th Apr 20157:00 amRNSFinal Results
14th Apr 20157:00 amRNSLaunch of in vitro service using 3D microtissues
31st Mar 20157:00 amRNSLaunch of new laboratory in its US facility
19th Mar 20157:00 amRNSLaunch of Short Time Exposure Service
12th Mar 20157:00 amRNSAppointment of Leader of Drug Transporter Team
22nd Dec 201412:12 pmRNSDirector Dealing
19th Nov 20141:26 pmRNSDirector Dealing 19 November 2014
14th Nov 20143:34 pmRNSDirector Dealing 14 November 2014
14th Nov 20147:00 amRNSTrading Update
13th Nov 20145:17 pmRNSHolding(s) in Company
14th Oct 20147:00 amRNSEnhanced SenCeeTox® technology
13th Oct 20142:14 pmRNSConversion of Loan Notes & TVR (Replacement)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.